Plain-English translation of NCT05866783 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a new blood test that measures certain patterns in blood proteins to predict whether liver cancer will come back after a transplant. Currently, doctors use standard selection criteria to choose transplant patients, but some patients still develop cancer recurrence. This study aims to validate whether this blood test can better identify which patients are at high risk of recurrence before and after their transplant.
Even with careful patient selection, about 15% of liver transplant patients with cancer experience cancer recurrence after surgery. This blood test could help doctors spot high-risk patients earlier and potentially catch cancer returning sooner—even before it shows up on regular imaging—so treatment can start faster.
You likely qualify if…
You likely don't qualify if…
You will have blood samples taken before your liver transplant and at scheduled time points after surgery to measure protein patterns in your blood. The study will track whether you develop cancer recurrence and compare your blood test results with your actual health outcomes. This is an observational study, meaning researchers are monitoring and collecting data rather than giving you a new medication or treatment.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Belgium